PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-115.67%
Negative EBIT growth while AXSM is at 23.84%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-115.67%
Negative operating income growth while AXSM is at 35.57%. Joel Greenblatt would press for urgent turnaround measures.
-133.51%
Negative net income growth while AXSM stands at 19.26%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-132.80%
Negative EPS growth while AXSM is at 20.49%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-132.80%
Negative diluted EPS growth while AXSM is at 20.49%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
31.94%
OCF growth 1.25-1.5x AXSM's 25.25%. Bruce Berkowitz would see if superior pricing or efficient operations explain the gap.
31.94%
FCF growth 1.25-1.5x AXSM's 25.25%. Bruce Berkowitz would see if capex decisions or cost controls create a cash flow advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-162.45%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-162.45%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-162.45%
Negative 3Y OCF/share CAGR while AXSM stands at 23.58%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-7367.52%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-7367.52%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-7367.52%
Negative 3Y CAGR while AXSM is 11.48%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-772.82%
Negative equity/share CAGR over 10 years while AXSM stands at 360.64%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-772.82%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-772.82%
Negative 3Y equity/share growth while AXSM is at 280.02%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-64.40%
Negative asset growth while AXSM invests at 7.23%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-61.26%
We have a declining book value while AXSM shows 35.76%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
8.45%
Debt growth far above AXSM's 2.81%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-27.70%
We cut SG&A while AXSM invests at 7.86%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.